Overall, the primary composite endpoint occurred in 331 patients of 1767 (18.7%) on Ozempic (1 mg) and 410 patients of 1766 (23.2%) on placebo (HR, 0.76 [95% CI: 0.66-0.88] P =0.0001 for superiority)
This milestone reinforces the companys commitment to expanding access to advanced therapies for chronic metabolic diseases, including type 2 diabetes
While many people lose weight with Ozempic, some may gain weight during treatment or after stopping the drug
Lowered blood pressure: Some studies suggest a modest reduction in blood pressure with Ozempic use
And with the right plan, adjusting meal timing, improving your posture, choosing safer supplements, you dont have to
Medi-Cal dropping coverage Perhaps the most significant change for low-income populations was Medi-Cal, California Medicaid program, dropping GLP-1 weight loss coverage effective January 1, 2026